Armin Reininger leaves Shire to join Sobi as new head of medical affairs

5 January 2017

Biotech firm Swedish Orphan Biovitrum (STO: SOBI) has announced the recruitment of Armin Reininger as senior vice president and head of global medical and scientific affairs.

Dr Reininger joins the Swedish rare disease specialists from Shire, where he spent six years developing the medical affairs team within hemophilia and hematology at both the regional and global level.

Sobi manufactures the active ingredient in ReFacto AF (moroctocog alfa) for Pfizer (NYSE: PFE), which sells the product globally. The firm's research and product portfolio is primarily focused on hemophilia, inflammation and genetic and metabolic diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK